candesartan has been researched along with Dyslipidemias in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 7.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 7.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 3.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 3.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pais, P | 1 |
| Jung, H | 1 |
| Dans, A | 1 |
| Zhu, J | 1 |
| Liu, L | 1 |
| Kamath, D | 1 |
| Bosch, J | 1 |
| Lonn, E | 1 |
| Yusuf, S | 1 |
| Hadi, NR | 1 |
| Yousif, NG | 1 |
| Abdulzahra, MS | 1 |
| Mohammad, BI | 1 |
| Al-Amran, FG | 1 |
| Majeed, ML | 1 |
| Yousif, MG | 1 |
| Ridker, PM | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Nakayama, T | 1 |
| Soma, M | 1 |
| Kitamura, N | 1 |
| Asai, S | 1 |
| Chen, J | 1 |
| Li, D | 1 |
| Schaefer, R | 1 |
| Mehta, JL | 1 |
1 trial available for candesartan and Dyslipidemias
| Article | Year |
|---|---|
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Asian People; Benzimid | 2019 |
4 other studies available for candesartan and Dyslipidemias
| Article | Year |
|---|---|
Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2013 |
Is Statin Monotherapy the Perfect Polypill?
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trial | 2016 |
Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2010 |
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2006 |